| Niacin, N-3 Fatty Acids and Insulin Resistance | Niacin, N-3 Fatty Acids and Insulin Resistance | NCT00286234 |
| Influence of combined therapy of niacin and statins on stem cell mobilization and inflammatory parameters in patients suffering from coronary artery disease – randomized clinical study - | Influence of combined therapy of niacin and statins on stem cell mobilization and inflammatory parameters in patients suffering from coronary artery disease – randomized clinical study - | EUCTR2005-003093-21-DE |
| Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care | Extended-Release Niacin/Lovastatin Versus Usual Care for Treatment of Dyslipidemia in a Primary Care Setting (EXTEND Study) | NCT00345657 |
| Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients | A Pilot Study of the Safety, Efficacy, and Tolerability of Extended-Release Niacin (Niaspan) for the Treatment of Elevated Non-HDL Cholesterol and Elevated Triglycerides in HIV-Infected Subjects | NCT00046267 |
| Time variability of flush-onset and flush tolerabililty in individuals given 500 mg niacin (nicotinic acid): a randomised controlled trial | | ISRCTN18054903 |
| Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication | Effect of Niacin ER/Lovastatin on Peak Walking Time and Claudication Onset Time in Patients With Intermittent Claudication | NCT00062556 |
| The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC | The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - a Matrix Design | NCT00071266 |
| Niacin Plus Statin to Prevent Vascular Events | AIM HIGH: Niacin Plus Statin to Prevent Vascular Events | NCT00120289 |
| Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST | Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST | NCT00082251 |
| An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032) | A Dose Ranging Study to Evaluate the Tolerability of MK0524 (Niacin (+) Laropiprant) and Its Effects on Niacin-Induced Acute Flushing in Lipid Clinic Patients and/or Normal Healthy Subjects | NCT00111891 |
| Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH) | Advancing Niacin by Inhibiting FLUSHing: (ANTI-FLUSH) | NCT00913081 |
| A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction | A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction | NCT00203476 |
| SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia | SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers | NCT00194402 |
| Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia | Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy | NCT00246376 |
| Impact of 12 weeks oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: a prospective, randomized, double-blind, placebo-controlled, monocentric clinical trial of phase IV | | ISRCTN48365122 |
| HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): A randomized trial of the long-term clinical effects of raising HDL cholesterol with niacin and MK-0524. - HPS2-THRIVE | HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): A randomized trial of the long-term clinical effects of raising HDL cholesterol with niacin and MK-0524. - HPS2-THRIVE | EUCTR2006-001885-17-FI |
| Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS) | An Open-Label Evaluation of the Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients With Dyslipidemia (OCEANS) | NCT00080275 |
| To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED) | Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia | NCT00271817 |
| The effect of niacin on sodium, phosphorus, parathyroid hormone (PTH) and vitamin D levels | The effect of niacin on sodium, phosphorus, parathyroid hormone (PTH) and vitamin D levels in hemodialysis patients | IRCT20190702044076N2 |
| Pharmacogenomics of nicotinic acid with laropiprant in Hong Kong Chinese patients with dyslipidemia | Pharmacogenomics of nicotinic acid with laropiprant in Hong Kong Chinese patients with dyslipidemia | ChiCTR-ONC-10001038 |
| GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures | GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures | NCT03462680 |
| Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study) - NICOLa | Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study) - NICOLa | EUCTR2006-005710-12-DE |
| The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis | The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis | NCT03163576 |
| Niacin to Improve Blood Flow in People With Sickle Cell Disease | Niacin Therapy to Improve Endothelial Function in Sickle Cell Disease | NCT00508989 |
| Effect of white egg and Niacin on hemodialysis patients | Evaluation the efficacy of Dietary Pasturized egg white with and without Niacinamide for phosphorus control in End Stage Renal Disease patients on Haemodialysis | IRCT2016102226390N5 |
| Niacin and other vitamin in treatment of acne vulgaris | Niacin and other vitamin in treatment of acne vulgaris | ChiCTR-IPR-15007592 |
| A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (ERN/LRPT) in Patients with Dyslipidemia | A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (ERN/LRPT) in Patients with Dyslipidemia | EUCTR2009-012772-27-AT |
| Metabolic changes by niacin | Study of metabolite changes by niacin supplement on patients with liver diseases - Niacin metabolism 2 | JPRN-jRCT1040240067 |
| Effect of MK0524A on Flushing Caused by Niacin (0524A-056) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Tolerability and Effect of MK0524A on Niacin-Induced Acute Flushing in Lipid Clinic Patients | NCT00533611 |
| Niacin Skin Flush Response in Patients With Schizophrenia | Niacin Skin Flush Response in Patients With Schizophrenia, Their First Degree Relatives, Bipolar Disorder Patients, and Healthy Controls | NCT02458924 |
| Niacin ameliorates DSS-induced colitis in mice by activation of D prostanoid receptor 1 | Niacin ameliorates DSS-induced colitis in mice by activation of D prostanoid receptor 1 | ChiCTR-IOR-15006400 |
| A pilot study on the effect of niacin on pulmonary arterial pressure | A pilot randomized double-blinded single-dose provocation study on the effect of niacin on pulmonary arterial pressure | ISRCTN12353191 |
| Effects of Niacin Therapy on Lipoprotein Composition and Function | Evaluation of the Effects of Niacin Therapy on Lipoprotein Composition and Function | NCT02322203 |
| Metabolic changes by niacin | Study of metabolite changes by niacin-related supplements on healthy subjects - Niacin metabolism | JPRN-jRCT1041230130 |
| Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels | Prospective Randomized Pilot Study of the Effect of Niaspan on Endothelial Function in HIV-infected Subjects With Low HDL Cholesterol Levels | NCT00986986 |
| A Pilot Study on Effect of add-on Sulforaphane to SSRIs and Application of Niacin Skin Flush Response Test in Major Depressive Disorder | A Pilot Study on Effect of add-on Sulforaphane to SSRIs and Application of Niacin Skin Flush Response Test in Major Depressive Disorder | NCT05148169 |
| The effects of nicotinic acid on hyperphosphatemia in dialysis patients of valiasr-Arak center | The effects of nicotinic acid on hyperphosphatemia in dialysis patients of valiasr-Arak center | IRCT138812153492N1 |
| Impact of 12 weeks of oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: A prospective, randomized, double-blind, placebo-controlled, monocentric clinical trial of phase IV - INEF | Impact of 12 weeks of oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: A prospective, randomized, double-blind, placebo-controlled, monocentric clinical trial of phase IV - INEF | EUCTR2005-005347-25-DE |
| A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED) | A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Type 2 Diabetes | NCT00618995 |
| Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid | Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid | NCT01159054 |
| Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females | Efficacy and Safety of Extended Release Niacin-Fenofibrate Combination and Monotherapy for the Treatment of Atherogenic Dyslipidemia in Obese Females | NCT03615534 |
| To determine if cardiovascular risk indices including postprandial hypertriglyceridaemia are modified favourably by nicotinic acid (niacin) in patients with polycystic ovary syndrome (PCOS) | To determine if cardiovascular risk indices including postprandial hypertriglyceridaemia are modified favourably by nicotinic acid (niacin) in patients with polycystic ovary syndrome (PCOS): a randomised double-blind placebo-controlled parallel study | ISRCTN37787683 |
| Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects | Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects | NCT01083329 |
| Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression | Double-Blind, Randomized, Placebo-Controlled, Single-Center, 2 Treatment, 3-Way Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 Mg Nicotinic Acid as Tablets in Healthy Subjects | NCT00176020 |
| TO DETERMINE IF CARDIOVASCULAR RISK INDICES INCLUDING POSTPRANDIAL HYPERTRIGLYCERIDAEMIA ARE MODIFIED FAVOURABLY BY NICOTINIC ACID (NIACIN) IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME (PCOS) | TO DETERMINE IF CARDIOVASCULAR RISK INDICES INCLUDING POSTPRANDIAL HYPERTRIGLYCERIDAEMIA ARE MODIFIED FAVOURABLY BY NICOTINIC ACID (NIACIN) IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME (PCOS) | EUCTR2009-015729-35-GB |
| Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT) | Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial | NCT00712049 |
| A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffering from dyslipidemia with uncontrolled elevated triglycerides. | A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffering from dyslipidemia with uncontrolled elevated triglycerides. | EUCTR2007-006393-29-FR |
| Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions | """Retrospective Study of Niacin (as a Vasodilator), Combined With a Topical Steroid (for Macular Edema), For CRVO, HRVO, BRVO.""" | NCT00500045 |
| To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions | Niacin (as a Vasodilator), and a Topical Steroid (for Macular Edema), Non-Ischemic CRVO,HRVO,BRVO | NCT00493064 |
| A study to investigate the effect of taking Nicotinic Acid Prolonged Release on abnormal artery blood vessel function in people with Type 2 diabetes who are on best-dose treatment with statin medications. | Effect of Nicotinic Acid Prolonged Release on endothelial dysfunction in subjects with Type 2 diabetes mellitus who are receiving optimal dose statin therapy | ACTRN12606000466549 |
| Effect of extended-release niacin on myocardial blood flow and flow reserve in patients with coronary artery disease treated with statins - NIFLO | Effect of extended-release niacin on myocardial blood flow and flow reserve in patients with coronary artery disease treated with statins - NIFLO | EUCTR2005-004218-34-DE |
| Abnormal serum triglyceride(form of fat)& low HDL cholesterol, important risk factors for heart & blood vessel diseases. Niacin, lipid lowering drug, is less used due to its side effects, can be minimized by adding Laropiprant. We study the drugs effect on both serum triglyceride & low HDL levels | The Impact Of Nicotinic acid (Niacin) And Laropiprant (LRPT) On Increased Triglyceride more than 300 And its implications with low High Density Lipoprotein Cholesterol (males less than 40 females less than 45) - TRIDL study | CTRI/2011/08/001977 |
| Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment | Qualitative and Quantitative Characterization of HDL in T2D After Fenofibrate or Niacin Treatment in Spanish Population | NCT02153879 |
| Assessment Of Vascular Health After Niacin Therapy (AVANT) | A 12-WEEK STUDY EVALUATING THE EFFECTS OF NIACIN ON VASCULAR HEALTH ASSESSED BY FLUORODEOXYGLUCOSE-PET/CT AND CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND MICROPARTICLES | NCT02003638 |
| A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) | A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia | NCT01294683 |
| To determine the efficacy and safety of a combination of Extended Release (ER) Niacin and Rosuvastatin as compared with Matching placebo and Rosuvastatin in patients with Mixed Dyslipidemia. | A randomized, double blind, comparative, multicentric study evaluating efficacy and tolerability of Extended Release Niacin and Rosuvastatin vs Matching placebo and Rosuvastatin in patients with Mixed Dyslipidemia. | CTRI/2011/091/000030 |
| Biosynthesis of PGD2 in Vivo | A Pilot Study to Measure Plasma and Urinary Prostaglandin D2 Metabolites Evoked by Niacin | NCT01275300 |
| Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis | A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Effects Of Niacin On Reverse Cholesterol Transport As Measured Using [1,2-3H]-Cholesterol (3H-cholesterol) in Healthy Volunteers. | NCT01250990 |
| Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients Deemed Appropriate for Further Lipid Modification. | NCT00664287 |
| To determine the efficacy and safety of a combination of Extended Release (ER) Niacin and Rosuvastatin as compared with Rosuvastatin alone in patients with Mixed Dyslipidemia. | A randomized, open label, comparative, multicentric study evaluating efficacy and tolerability of Extended Release Niacin and Rosuvastatin vs Rosuvastatin alone in patients with Mixed Dyslipidemia. | CTRI/2010/091/003016 |
| Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease | Lipid Efficacy and Effects on HDL-C Metabolism of the Extended Release Niacin/Laropiprant Combination Added to Usual Therapy in Patients With Cardiovascular Disease and Low HDL-C That Did Not Achieve the Optional Very Low LDL-C Goal | NCT01308203 |
| A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers | A Study to Evaluate the Ability of the HM74A Agonist GSK256073A to Block Niacin-induced Flushing in Healthy Adult Subjects | NCT00608699 |
| The effect of two topical drugs fluorouracil 5% and niacin amide 1% in the treatment of patients with actinic keratosis | Clinical trial of Comparison of the efficacy of two topical drugs fluorouracil 5% and niacin amide 1% in the treatment of patients with actinic keratosis | IRCT20220519054920N1 |
| Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119) | Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of TREDAPTIVE Tablet in Usual Practice | NCT01228019 |
| Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis | Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: The Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial | NCT01221402 |
| Effect of Niacin/ Laropiprant on postprandial lipoprotein and glucose metabolism in patients with severe dyslipoproteinemia | Effect of Niacin/ Laropiprant on postprandial lipoprotein and glucose metabolism in patients with severe dyslipoproteinemia | EUCTR2010-019954-42-DE |
| Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin | A Randomized, Double-blind, Parallel, Multicenter, Placebo-controlled, Prospective Study to Evaluate the Functionality of the Flushing ASsessment Tool (FAST) in Subjects Administered Niaspan® Plus Acetylsalicylic Acid (ASA), Niaspan® Plus ASA Placebo or Niaspan® Placebo Plus ASA Placebo Daily for Six Weeks | NCT00630877 |
| The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker | | NCT01071525 |
| Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) | A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia | NCT01274559 |
| Niacin on Immune Activation : a Proof-of-concept Study | Role of Extended-release Niacin on Immune Activation in HIV-infected Patients Treated With Antiretroviral Therapy: a Proof-of-concept Study | NCT02018965 |
| Evaluation of the therapeutic effect of a combination drug including Apocynin, Niacin, and Tannin on COVID-19 | Evaluation of the protective effect of a combination drug including Apocynin, Niacin, and Tannin on prevention of cardiovascular and respiratory morbidities and mortality in COVID-19 infection: A Clinical Trial | IRCT20200418047122N1 |
| Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease | The Effects of Chronic High-density Lipoprotein (HDL) Elevation With Extended Release Niacin on Peripheral Arterial Disease | NCT01391377 |
| Effects of Niacin On Fatty Acid Trapping | Effect of Niacin On Fatty Acid Trapping | NCT01984073 |
| Short-term Effect of Extended-release Niacin on Endothelial Function. | Short-term Effect of Extended-release Niacin With and Without the Addition of Laropiprant on Endothelial Function | NCT01942291 |
| Evaluation of novel topical niacin nutriceuticals for improving gut microbiota and metabolic health | Evaluation of novel topical niacin nutriceuticals for improving gut microbiota and metabolic health | DRKS00016344 |
| ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART | ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART | NCT01683656 |
| A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158) | A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ER Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia | NCT01583647 |
| Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia | Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia | NCT01010516 |
| Nicotinic Acid and Lipoprotein (a): The Effect of Extended Release Nicotinic Acid on Plasma Lipoprotein (a), its Isoforms and apo(a) Fragments | Effect Of Extended Release Nicotinic Acid On Plasma Lipoprotein (a), Its Isoforms And Apo(a) Fragments. | ACTRN12611000252910 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients. | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients. | EUCTR2008-000465-37-FR |
| Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108) | A 16-Week, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Extended Release Niacin/Laropiprant in South and Southeast Asians Not on a Lipid Modulating Agent, With Decreased High-Density Lipoprotein Cholesterol and Low- Density Lipoprotein Cholesterol at or Below NCEP ATP III Goal | NCT01414166 |
| MK0524A Phase IIb Study (0524A-011)(COMPLETED) | Part A: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of MK0524 Compared to Placebo Part B: A Dose-Ranging Study to Evaluate the Tolerability of MK0524 and Its Effects on Niacin-Induced Flushing in Lipid Clinic Patients | NCT00536237 |
| "The Slo-Niacin trial. A trial of phosphate lowering agent ""slo-Niacin"" in patients on haemodialysis." | The effect of slow release nicotinic acid on serum phosphate in patients with end stage renal failure on maintenance haemodialysis and with persistently high serum phosphate levels. | ACTRN12611000500954 |
| Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) | A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia | NCT01335997 |
| The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients | The Impact of Tredaptive (ER Niacin/Laropiprant) Compared to Placebo on Brachial Artery Endothelial Function in Patients With Stable Coronary Artery Disease on Statin Therapy | NCT01052311 |
| Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate | Effect of HDL-Raising Therapies on Endothelial Function, Lipoproteins, and Inflammation in HIV-infected Subjects With Low HDL Cholesterol: A Phase II Randomized Trial of Extended Release Niacin vs. Fenofibrate | NCT01426438 |
| Niacin/Laropiprant and Endothelial Function | A Double Blind, Randomized Study to Compare Influence of Niacin/Laropiprant on Functional and Morphological Characteristics of Arterial Wall and Parameters of Inflammation in Subjects With Coronary Heart Disease Already Treated With a Statin | NCT01126073 |
| The effects of Nicotinic acid on serum phosphorus, PTH and lipid profile in dialysis patients . | The effects of Nicotinic acid on serum phosphorus, PTH and lipid profile in dialysis patients . | IRCT201402212954N4 |
| Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069) | A Multicenter, Randomized, Double-Blind, Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients With Type 2 Diabetes | NCT00485758 |
| The effect of Niacin on post-meal blood fat transport in men with type 2 diabetes | Reducing Cardiovascular Risk in Type 2 Diabetes: The effect of nicotinic acid prolonged release on postprandial lipoproetin metabolism in men with type 2 diabetes. | ACTRN12609000448246 |
| Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL | Efecto Del ácido nicotínico Sobre la composición de Las lipoproteínas de Alta Densidad (HDL) y la función Del Endotelio Arterial en Los Pacientes Con cardiopatía isquémica Prematura y Concentraciones Elevadas de Colesterol-HDL | NCT01450410 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 36-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients with Type 2 Diabetes Mellitus - Extended Release Niacin/Laropiprant-Diabetes | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 36-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients with Type 2 Diabetes Mellitus - Extended Release Niacin/Laropiprant-Diabetes | EUCTR2007-002515-75-FI |
| MK0524A Bioequivalence Study (0524A-059) | An Open Label, Randomized, 2-Period, Crossover Study to Establish the Definitive Bioequivalence of Niacin and MK0524 of 2 Sources of MK0524A Tablets | NCT00944645 |
| MK0524B Bioequivalence Study (0524B-070) | An Open-Label, Definitive Bioequivalence Study to Compare the Pharmacokinetics of the Simvastatin, Nicotinic Acid, and MK0524 (Laropiprant) Components of a Formulation of MK0524B With That of Zocor™ and MK0524A Tablets | NCT00943124 |
| Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) | A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia. | NCT00479388 |
| A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Statin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia. - Extended Release Niacin/Laropiprant – Lipids | A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Statin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia. - Extended Release Niacin/Laropiprant – Lipids | EUCTR2007-002017-39-DK |
| Role of Prostaglandins on Niacin-Induced Flushing | Exploring the Role of Prostaglandin D2 and the DP1 Receptor on Nicotinic Acid Induced Flushing | NCT00930839 |
| An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME) | SUPREME: A 12-Week, Open-Label, Multicenter Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia | NCT00465088 |
| Niacin and Endothelial Function in Early CKD | Does Raising HDL-C With Niacin Improve Endothelial Function in Early CKD? | NCT00852969 |
| A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED) | A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Hypercholesterolemia | NCT00769132 |
| Niacin skin flushing response in evaluating the efficacy of modified electroconvulsive therapy in schizophrenia | Changes in psychiatric symptoms and niacin skin flushing response after modified electroconvulsive therapy, and the correlation between them in schizophrenia | ISRCTN12245577 |
| EFFECTS OF NICOTINIC ACID PLUS SIMVASTATIN VS.SIMVASTATIN ALONE ON CAROTID AND FEMORAL INTIMA-MEDIA THICKNESS IN PATIENTS WITH PERIPHERAL ARTERY DISEASE (NASCIT) –A RANDOMIZED CONTROLLED TRIAL - NASCIT | EFFECTS OF NICOTINIC ACID PLUS SIMVASTATIN VS.SIMVASTATIN ALONE ON CAROTID AND FEMORAL INTIMA-MEDIA THICKNESS IN PATIENTS WITH PERIPHERAL ARTERY DISEASE (NASCIT) –A RANDOMIZED CONTROLLED TRIAL - NASCIT | EUCTR2007-000197-24-AT |
| Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis | ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS) | NCT00397657 |
| Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery | Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery | NCT00796887 |
| Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED) | A Randomized Clinical Trial to Evaluate the Effects of High Dose Statin and Niacin Therapy on Excised Plaque Biomarkers in Patients Undergoing Carotid Endarterectomy (CEA) | NCT00804843 |
| A Randomized Clinical Trial to Evaluate the Effects of High Dose Statin and Niacin Therapy on Excised Plaque Biomarkers in Patients Undergoing Carotid Endarterectomy (CEA) - Carotid Plaque POC Study | A Randomized Clinical Trial to Evaluate the Effects of High Dose Statin and Niacin Therapy on Excised Plaque Biomarkers in Patients Undergoing Carotid Endarterectomy (CEA) - Carotid Plaque POC Study | EUCTR2008-008006-46-CZ |
| Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia | Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia | NCT00304993 |
| Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL | A Randomized, Double Blind, Placebo Controlled Trial of Pioglitazone and Niacin Extended Release in Non-diabetic Patients With Metabolic Syndrome | NCT00300365 |
| Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054) | A PARALLEL, DOUBLE-BLIND, MULTICENTER, WORLDWIDE STUDY TO EVALUATE THE TOLERABILITY OF MK-0524A AGAINST PROLONGED RELEASE NIACINE | PER-074-06 |
| Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL) | Exercise Versus Extended-Release Niacin in Patients With Coronary Heart Disease and Low High-Density Lipoproteins (HDL) Cholesterol: Effect on Lipid Profile and Endothelial Function | NCT00298909 |
| Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054) | A Worldwide, Multicenter, Double-Blind, Parallel Study to Evaluate the Tolerability of MK0524A Versus Niacin Extended-Release | NCT00378833 |
| Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED) | A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Study to Evaluate the Efficacy of MK0524 to Improve Tolerability of Extended Release Niacin | NCT00376584 |
| A Worldwide, Multicenter, Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy of MK-0524 to Improve Tolerability of Extended Release Niacin - Effect of an Investigational Compound on Tolerability of Extended Release Niacin | A Worldwide, Multicenter, Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy of MK-0524 to Improve Tolerability of Extended Release Niacin - Effect of an Investigational Compound on Tolerability of Extended Release Niacin | EUCTR2006-003107-39-DE |
| The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study) | Randomized Clinical Trial to Study the Effect of Extended Release Niacin on Endothelial Function, Oxidative Stress and Endothelial Progenitor Cells in Patients With the Metabolic Syndrome. | NCT00346970 |
| Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD) | Influence of Combined Therapy of Niacin and Statins on Stem Cell Mobilization and Inflammatory Parameters in Patients Suffering From Coronary Artery Disease – Randomized Clinical Study - | NCT00431145 |
| Stimulating Fat Tissue Storage with Niacin to Reduce Fat Accumulation in the Liver. | Stimulating Adipose Tissue Fatty Acid Disposal with Low-dose, Postprandial, Intermittent Niacin for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD). | NCT06843148 |
| Study the Effect of Niacin on Lipoprotein (a) Concentration and Hyperphosphatemia in Hemodialysis Patients | Potential Effect of Niacin on Lipoprotein (a) Concentration and Hyperphosphatemia in End-Stage Renal Disease Patients Undergoing Hemodialysis | NCT06406140 |
| Nicotinic Acid for the Treatment of Alzheimer's Disease | Nicotinic Acid for the Treatment of Alzheimer's Disease | NCT06582706 |
| Niacin Supplementation in Healthy Controls and Mitochondrial Myopathy Patients | The Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance in Healthy Controls and Mitochondrial Myopathy Patients | NCT03973203 |
| The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study | The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study | NCT00953667 |
| PUBLIC TITLE ; Effect of niacin on hyperphosphatemia in chronic kidney disease (stages 3-5) patients | Effect of niacin on hyperphosphatemia in chronic kidney disease (stages 3-5) patients. A randomized double blind placebo controlled trial. | PACTR201905507865682 |
| Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus | Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus | NCT03867500 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 WEEK STUDY, TO EVALUATE THE EFFICACY AND SAFETY OF PROLONGED RELEASE / LAROPIPRANT NIACIN WHEN ADDED TO CURRENT LIPID-MODIFYING THERAPY IN DISLIPIDEMIC PATIENTS. | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 WEEK STUDY, TO EVALUATE THE EFFICACY AND SAFETY OF PROLONGED RELEASE / LAROPIPRANT NIACIN WHEN ADDED TO CURRENT LIPID-MODIFYING THERAPY IN DISLIPIDEMIC PATIENTS. | PER-046-08 |
| Niacin for Parkinsons Disease | NAPS: Niacin for Parkinsons Disease | NCT03808961 |
| Study of Niacin in Glioblastoma | A Phase I-II Study of Niacin in Patients With Newly Diagnosed Glioblastoma Receiving Concurrent Radiotherapy and Temozolomide Followed by Monthly Temozolomide | NCT04677049 |
| A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102) | A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of ERN/LRPT in Patients With Dyslipidemia | NCT00961636 |
| Evaluation of Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With Prediabetes | A Phase I, Double-blind, Randomised, Placebo-controlled, Single-ascending and Multiple-ascending Dose Trial to Evaluate the Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With Prediabetes | NCT06378125 |
| Effect of Nicotinic Acid as Add on Therapy in Patients Receiving ß Blocker for Prophylaxis of Moderate to Severe Migraine | Effect of Nicotinic Acid as add-on Therapy in Patients Receiving ß Blocker for Prophylaxis of Moderate to Severe Migraine: A Randomized, Double-blind, Placebo-controlled Trial | NCT05846373 |
| A Phase I, double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes | A Phase I, double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes - CIR-NA I | DRKS00030865 |
| A Study to Investigate Nicotinic Acid on VEGFR Inhibitor-Associated Hand-Foot Skin Reactions | Efficacy of Nicotinic Acid for VEGFR Inhibitor-Associated Hand-Foot Skin Reactions in Solid Tumor Patients: a Randomised Controlled Phase 2 Trial | NCT04242927 |
| A randomized, multicenter, open-label, two-arm, parallel, phase III study to evaluate the efficacy and safety of nicotinic acid administered in combination with simvastatin for 6 months in comparison to simvastatin therapy alone in inhibiting the progression of atherosclerosis in patients with carotid arteries stenosis and dyslipidemia. | A randomized, multicenter, open-label, two-arm, parallel, phase III study to evaluate the efficacy and safety of nicotinic acid administered in combination with simvastatin for 6 months in comparison to simvastatin therapy alone in inhibiting the progression of atherosclerosis in patients with carotid arteries stenosis and dyslipidemia. | EUCTR2014-003213-29-PL |
| Carbohydrate dependence during simulated half-marathon performance | The effect of blocking lipolysis via Nicotinic Acid on simulated half-marathon performance in well trained runners | ACTRN12614000634673 |
| Carbohydrate dependence during endurance exercise (The effect of Nicotinic acid on endurance performance in trained cyclists) | The effect of Nicotinic acid on endurance performance in trained cyclists | ACTRN12614000629639 |
| The Effect of Niacin Supplementation, Statin Medication and Nutrition Interventions on HIV-infected Children Receiving Anti-retroviral Therapy at Doctor George Mukhari Academic Hospital, Gauteng, South Africa | The Effect of Niacin Supplementation, Statin Medication and Nutrition Interventions on HIV-infected Children Receiving Anti-retroviral Therapy at Doctor George Mukhari Academic Hospital, Gauteng, South Africa | PACTR201810851895495 |
| Effects of Ketones and Niacin in Heart Failure Patients | Effects of Ketones and Niacin in Heart Failure Patients | NCT04703361 |
| NiaMIT Continuation With Early-stage Mitochondrial Myopathy Patients | NiaMIT (NiaMIT_0001) Continuation for Early-stage Mitochondrial Myopathy Patients to Investigate the Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance | NCT04538521 |
| The effect of niacin in the treatment of depression | Evaluation of niacin addition to Escitalopram in patients with depression | IRCT20231207060286N1 |
| A Study of Niacin Regulation | Niacin Regulation of Regional Adipose Tissue Lipolysis | NCT06175403 |
| Diagnosis of Depressive Disorder Malinger Using the Niacin Skin Response Test (NSRT) | Biological Diagnostic Techniques for the Diagnosis of Depressive Disorders Malinger Based on the Niacin Skin Response Test (NSRT) | NCT06382532 |
| A Comparative study on the effet of Niacin and Sevelamer on decreasing the phosphorous in dialysis patients referring to dialysis department of 5azar medical education center of gorgan in2019(1398) | A Comparative study on the effet of Niacin and Sevelamer on decreasing the phosphorous in dialysis patients referring to dialysis department of 5azar medical education center of gorgan in2019(1398) | IRCT20190324043106N1 |
| Clinical trial of niacin on premature ovarian failure | Clinical trial of niacin on premature ovarian failure | ChiCTR2100045312 |
| Study on the precise treatment of schizophrenia patients in the subgroup of blunted niacin response | Effects of fish oil supplementation on niacin skin flushing responses, psychotic symptoms and cognition in the subgroup of schizophrenia patients with blunted niacin responses | ISRCTN10306750 |
